Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?

Area of Science:

• Pediatrics
• Virology
• Immunology

Background:

• Respiratory syncytial virus (RSV) is a primary cause of severe respiratory infections in children globally, leading to significant infant hospitalizations.
• Current RSV treatment is symptomatic, with no widely available vaccines, and palivizumab, the sole licensed passive immunoprophylaxis, is costly and restricted to high-risk infants.
• Unnecessary antibiotic prescriptions for RSV bronchiolitis are common due to fear of bacterial coinfection, contributing to resistance and increased healthcare costs.

Purpose of the Study:

• To review the current application of palivizumab for RSV prevention.
• To summarize ongoing clinical and preclinical research for novel monoclonal antibodies (mAbs) targeting RSV.
• To explore more cost-effective passive immunization strategies for broader infant protection against RSV.

Main Methods:

• Literature review of palivizumab usage guidelines and efficacy.
• Analysis of clinical trial data for emerging RSV passive immunization candidates.
• Preclinical study evaluation of novel monoclonal antibodies (mAbs) for RSV.

Main Results:

• Palivizumab's high cost limits its use, despite many hospitalized infants not meeting strict eligibility criteria.
• A significant number of infants hospitalized with RSV do not qualify for current passive prophylaxis.
• Multiple new mAbs are in development, aiming for improved cost-effectiveness and broader applicability.

Conclusions:

• There is a critical need for more accessible and cost-effective RSV passive immunoprophylaxis options beyond palivizumab.
• Development of new mAbs is crucial to provide RSV protection to a wider infant population.
• Advancing RSV prevention strategies is essential to reduce the global burden of infant respiratory infections.